Page last updated: 2024-11-08

aspartic acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma

aspartic acid has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 14 studies

Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.

Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.

Research Excerpts

ExcerptRelevanceReference
"Treatment of pediatric acute lymphoblastic leukemia (ALL) with pegaspargase exploits ALL cells dependency on asparagine."1.62Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia. ( Bielawski, JP; Cohen, A; Connors, J; Dunn, KA; Forbrigger, Z; Kulkarni, K; Langille, MGI; MacDonald, T; Penny, SL; Rahman, M; Stadnyk, AW; Van Limbergen, J, 2021)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (14.29)18.2507
2000's4 (28.57)29.6817
2010's6 (42.86)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Muneer, F1
Siddique, MH1
Azeem, F1
Rasul, I1
Muzammil, S1
Zubair, M1
Afzal, M1
Nadeem, H1
Dunn, KA1
Forbrigger, Z1
Connors, J1
Rahman, M1
Cohen, A1
Van Limbergen, J1
Langille, MGI1
Stadnyk, AW1
Bielawski, JP1
Penny, SL1
MacDonald, T1
Kulkarni, K1
Zuo, S1
Zhang, T1
Jiang, B1
Mu, W1
Nath, CE1
Dallapozza, L1
Eslick, AE1
Misra, A1
Carr, D1
Earl, JW1
Ficek, K1
Blamek, S1
Syguła, D1
Miszczyk, L1
Sońta-Jakimczyk, D1
Tarnawski, R1
Chen, SH1
Yang, W1
Fan, Y1
Stocco, G1
Crews, KR1
Yang, JJ1
Paugh, SW1
Pui, CH1
Evans, WE1
Relling, MV1
Aslan, H1
Donmez, FY1
Hekimoglu, OK1
Tore, HG1
Saarinen-Pihkala, UM1
Parto, K1
Riikonen, P1
Lähteenmäki, PM1
Békàssy, AN1
Glomstein, A1
Möttönen, M1
Steiner, M1
Hochreiter, D1
Kasper, DC1
Kornmüller, R1
Pichler, H1
Haas, OA1
Pötschger, U1
Hutter, C1
Dworzak, MN1
Mann, G1
Attarbaschi, A1
Holownia, A1
Trofimiuk, E1
Krawczuk-Rybak, M1
Jakubow, P1
Kaliszewski, J1
Muszynska-Roslan, K1
Braszko, JJ1
Parr, IB1
Boehlein, SK1
Dribben, AB1
Schuster, SM1
Richards, NG1
Boos, J1
Werber, G1
Ahlke, E1
Schulze-Westhoff, P1
Nowak-Göttl, U1
Würthwein, G1
Verspohl, EJ1
Ritter, J1
Jürgens, H1
Chan, YL1
Roebuck, DJ1
Yuen, MP1
Yeung, KW1
Lau, KY1
Li, CK1
Chik, KW1
Aslanian, AM1
Kilberg, MS1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111]Phase 3501 participants (Actual)Interventional2000-07-08Completed
2157GCCC: A Phase I Trial of Calaspargase Pegol-mknl in Combination With High Dose Cytarabine and Idarubicin in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia[NCT04953780]Phase 124 participants (Anticipated)Interventional2021-09-27Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)

"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion

InterventionPercent change (Mean)
4 hr-44
24 hr-50

Continuous Complete Remission Since Week 56 Therapy.

CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years

InterventionPercentage of participants (Number)
Patients With High Risk of CNS Relapse92.2

Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).

Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)

Interventionpmol/1,000,000,000 cells (Mean)
4 hr1688
24 hr2521

Overall Event-free Survival (EFS)

EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years

InterventionPercentage of Participants (Number)
Total Therapy87.3

Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Interventionarbitrary units (Median)
Prednisolone-sensitive cellsPrednisolone-resistant cells
Total Therapy341.3447.9

Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Interventionarbitrary units (Median)
Prednisolone-sensitive cellsPrednisolone-resistant cells
Total Therapy41.2110.7

Minimal Residual Disease (MRD)

Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)

Interventionparticipants (Number)
Negative <0.01%Positive >= 0.01%
Total Therapy390102

Reviews

2 reviews available for aspartic acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
Microbial L-asparaginase: purification, characterization and applications.
    Archives of microbiology, 2020, Volume: 202, Issue:5

    Topics: Ammonia; Asparaginase; Asparagine; Aspartic Acid; Bacteria; Fungi; Hodgkin Disease; Humans; Phylogen

2020
Recent research progress on microbial L-asparaginases.
    Applied microbiology and biotechnology, 2015, Volume: 99, Issue:3

    Topics: Acrylamide; Asparaginase; Asparagine; Aspartic Acid; Bacteria; Fungi; Humans; Hydrolysis; Precursor

2015

Trials

1 trial available for aspartic acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
RALLE pilot: response-guided therapy for marrow relapse in acute lymphoblastic leukemia in children.
    Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Bone Marrow; Child; Child

2012

Other Studies

11 other studies available for aspartic acid and Precursor Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia.
    Leukemia & lymphoma, 2021, Volume: 62, Issue:13

    Topics: Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Genes, Bacterial; Glutamic Ac

2021
An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
    Biomedical chromatography : BMC, 2009, Volume: 23, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Child, Preschool;

2009
Evaluation of the late effects of CNS prophylactic treatment in childhood acute lymphoblastic leukemia (ALL) using magnetic resonance spectroscopy.
    Acta neurochirurgica. Supplement, 2010, Volume: 106

    Topics: Adolescent; Aspartic Acid; Brain Injuries; Case-Control Studies; Child; Child, Preschool; Choline; C

2010
A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity.
    Leukemia, 2011, Volume: 25, Issue:1

    Topics: Antineoplastic Agents; Asparaginase; Aspartic Acid; Cell Line; Genome-Wide Association Study; Humans

2011
The magnetic resonance spectroscopy findings of extrapontine myelinolysis in a patient with acute lymphoblastic leukemia.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2012, Volume: 33, Issue:2

    Topics: Aspartic Acid; Choline; Creatine; Female; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spe

2012
Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlin-Frankfurt-Münster-based induction therapy for childhood acute lymphoblastic leukemia.
    Leukemia & lymphoma, 2012, Volume: 53, Issue:9

    Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; A

2012
Cerebrospinal fluid excitatory amino acids and tau protein in children with acute lymphoblastic leukemia treated according to the BFM protocol.
    Acta haematologica, 2004, Volume: 112, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Aspartic Acid; Child; Daunorubicin; Ex

2004
Mapping the aspartic acid binding site of Escherichia coli asparagine synthetase B using substrate analogs.
    Journal of medicinal chemistry, 1996, Jun-07, Volume: 39, Issue:12

    Topics: Alkylation; Antineoplastic Agents; Asparagine; Aspartate-Ammonia Ligase; Aspartic Acid; Bacterial Pr

1996
Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:9

    Topics: Adolescent; Antineoplastic Agents; Asparaginase; Asparagine; Aspartic Acid; Child; Child, Preschool;

1996
Long-term cerebral metabolite changes on proton magnetic resonance spectroscopy in patients cured of acute lymphoblastic leukemia with previous intrathecal methotrexate and cranial irradiation prophylaxis.
    International journal of radiation oncology, biology, physics, 2001, Jul-01, Volume: 50, Issue:3

    Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Aspartic Acid; Brain; Brain Infarction; Cerebrov

2001
Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
    The Biochemical journal, 2001, Aug-15, Volume: 358, Issue:Pt 1

    Topics: Amino Acids; Asparaginase; Aspartate-Ammonia Ligase; Aspartic Acid; Biological Transport; Cell Divis

2001